finilac mixtúra, lausn 50 míkróg/ml
le vet beheer b.v. - cabergolinum inn - mixtúra, lausn - 50 míkróg/ml
benestermycin vet. spenalyf, smyrsli
boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli
procamidor vet. stungulyf, lausn 20 mg/ml
vetviva richter gmbh - procainum hýdróklóríð - stungulyf, lausn - 20 mg/ml
paxetin filmuhúðuð tafla 20 mg
teva b.v.* - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg
seroxat filmuhúðuð tafla 20 mg
glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg
seroxat filmuhúðuð tafla 10 mg
glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 10 mg
sumatriptan bluefish tafla 100 mg
bluefish pharmaceuticals ab - sumatriptanum súkkínat - tafla - 100 mg
sumatriptan bluefish tafla 50 mg
bluefish pharmaceuticals ab - sumatriptanum súkkínat - tafla - 50 mg
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formóteróli fúmarat tvíhýdrat, Þannig brómíð - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
riarify (previously chf 5993 chiesi farmaceutici s.p.a.)
chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - viðhald meðferð í fullorðinn sjúklinga með í meðallagi til alvarlega langvinn veikindi í lungum (llt) sem eru ekki nægilega meðhöndluð með sambland af andað barksteri og langverkandi beta-2-örva (fyrir áhrif á einkenni stjórn og koma í veg fyrir tilvikum sjá kafla 5.